(Q44396642)

2 December 2017

title

Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study (English)

1 reference

2 December 2017

1 reference

2

1 reference

2 December 2017

Alexander Imhof

1

1 reference

2 December 2017

Andreas Schaffner

series ordinal

3

1 reference

2 December 2017

language of work or name

English

0 references

publication date

4 April 2003

1 reference

Clinical Infectious Diseases

2 December 2017

published in

1 reference

2 December 2017

volume

36

1 reference

2 December 2017

issue

8

1 reference

2 December 2017

page(s)

943-951

1 reference

Antifungal therapy in 'bone marrow failure'.

2 December 2017

cites work

1 reference

Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients

21 January 2018

1 reference

Pharmacokinetics and toxicity of continuous infusion amphotericin B in cancer patients

21 January 2018

1 reference

Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial

21 January 2018

1 reference

Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model

21 January 2018

1 reference

Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection.

21 January 2018

1 reference

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

21 January 2018

1 reference

Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy

21 January 2018

1 reference

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

21 January 2018

1 reference

Pretreatment regimens for adverse events related to infusion of amphotericin B.

21 January 2018

1 reference

Prevention of amphotericin-B-induced nephrotoxicity by loading with sodium chloride: a report of 1291 days of treatment with amphotericin B without renal failure

21 January 2018

1 reference

Sodium depletion enhances nephrotoxicity of amphotericin B

21 January 2018

1 reference

Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study

21 January 2018

1 reference

Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rate model of pulmonary aspergillosis.

21 January 2018

1 reference

Amphotericin B nephrotoxicity in humans decreased by salt repletion

21 January 2018

1 reference

Hepatotoxicity possibly caused by amphotericin B.

21 January 2018

1 reference

Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlle

21 January 2018

1 reference

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/368312

1 reference

2 December 2017

1 reference